ArticleACS omega2026
Beyond MIDAS: An
Article in ACS omega, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Integrins are essential transmembrane receptors that mediate bidirectional signaling between the extracellular matrix (ECM) and the cytoskeleton. Among them, αvβ3 and α5β1 are key regulators of angiogenesis, metastasis, and tumor progression. The laminin-1-derived C16 peptide (KAFDITYVRLKF) interacts with both integrins, but the molecular determinants governing its specificity remain unclear. Here, we applied an integrative computational approach combining ADMET predictions, molecular docking, and all-atom molecular dynamics (MD) simulations to characterize C16 pharmacokinetics and its predicted binding modes to αvβ3 and α5β1.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.